EBS
Emergent Biosolutions Inc
NYSE: EBS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$5.90
-5.60% today
Updated 2026-11-04
Market cap
$330.20M
P/E ratio
—
P/S ratio
0.43x
EPS (TTM)
$-3.22
Dividend yield
—
52W range
$4 – $14
Volume
1.2M
Emergent Biosolutions Inc (EBS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$5.90
12-Month target
$6.47
2030 Target
—
Intrinsic (DCF)
$33.61
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.1B | $1.0B | $1.0B | $0.7B | $0.6B | $0.5B | $0.5B | $0.4B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -13.98% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -23.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.